Cargando…

Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system

BACKGROUND: In recent years, personalized medicine (PM) has become a highly regarded line of development in medicine. Yet, it is still a relatively new field. As a consequence, the discussion of its future developments, in particular of its ethical implications, in most cases can only be anticipativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Schleidgen, Sebastian, Marckmann, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681604/
https://www.ncbi.nlm.nih.gov/pubmed/23705623
http://dx.doi.org/10.1186/1472-6939-14-20
_version_ 1782273282954756096
author Schleidgen, Sebastian
Marckmann, Georg
author_facet Schleidgen, Sebastian
Marckmann, Georg
author_sort Schleidgen, Sebastian
collection PubMed
description BACKGROUND: In recent years, personalized medicine (PM) has become a highly regarded line of development in medicine. Yet, it is still a relatively new field. As a consequence, the discussion of its future developments, in particular of its ethical implications, in most cases can only be anticipative. Such anticipative discussions, however, pose several challenges. Nevertheless, they play a crucial role for shaping PM’s further developments. Therefore, it is vital to understand how the ethical discourse on PM is conducted, i.e. on what – empirical and normative – assumptions ethical arguments are based regarding PM’s current and future developments. METHODS: To gather this information, we conducted a qualitative interview study with stakeholders in the German health care system. Our purposive sample included 17 representatives of basic research, clinical research, health economics, regulatory authorities, reimbursement institutions, pharmaceutical industry, patient organizations, as well as clinicians and legal experts involved in PM developments or policy making. We used an interview guide with open-ended questions and analyzed transcriptions of the interviews by means of qualitative content analysis. RESULTS: The respondents addressed a multitude of concerns in the context of research on as well as application of personalized preventive and therapeutic measures both on the individual and on the societal level. Interestingly, regarding future developments of PM the ethical evaluation seemed to follow the rule: the less likely its application, the more problematic a PM measure is assessed. The more likely its application, on the other hand, the less problematic it is evaluated. CONCLUSIONS: The results of our study suggest re-focusing the ethical discourse on PM in Germany towards a constructive ethical monitoring which ensures to include only, nevertheless all of the actual and/or potential concerns that are ethically relevant in order to allow balancing them against the actual and potential ethically relevant benefits of PM measures. To render this possible, we propose a strategy for evaluating ethical concerns in the context of PM.
format Online
Article
Text
id pubmed-3681604
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36816042013-06-14 Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system Schleidgen, Sebastian Marckmann, Georg BMC Med Ethics Research Article BACKGROUND: In recent years, personalized medicine (PM) has become a highly regarded line of development in medicine. Yet, it is still a relatively new field. As a consequence, the discussion of its future developments, in particular of its ethical implications, in most cases can only be anticipative. Such anticipative discussions, however, pose several challenges. Nevertheless, they play a crucial role for shaping PM’s further developments. Therefore, it is vital to understand how the ethical discourse on PM is conducted, i.e. on what – empirical and normative – assumptions ethical arguments are based regarding PM’s current and future developments. METHODS: To gather this information, we conducted a qualitative interview study with stakeholders in the German health care system. Our purposive sample included 17 representatives of basic research, clinical research, health economics, regulatory authorities, reimbursement institutions, pharmaceutical industry, patient organizations, as well as clinicians and legal experts involved in PM developments or policy making. We used an interview guide with open-ended questions and analyzed transcriptions of the interviews by means of qualitative content analysis. RESULTS: The respondents addressed a multitude of concerns in the context of research on as well as application of personalized preventive and therapeutic measures both on the individual and on the societal level. Interestingly, regarding future developments of PM the ethical evaluation seemed to follow the rule: the less likely its application, the more problematic a PM measure is assessed. The more likely its application, on the other hand, the less problematic it is evaluated. CONCLUSIONS: The results of our study suggest re-focusing the ethical discourse on PM in Germany towards a constructive ethical monitoring which ensures to include only, nevertheless all of the actual and/or potential concerns that are ethically relevant in order to allow balancing them against the actual and potential ethically relevant benefits of PM measures. To render this possible, we propose a strategy for evaluating ethical concerns in the context of PM. BioMed Central 2013-05-24 /pmc/articles/PMC3681604/ /pubmed/23705623 http://dx.doi.org/10.1186/1472-6939-14-20 Text en Copyright © 2013 Schleidgen and Marckmann; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Schleidgen, Sebastian
Marckmann, Georg
Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system
title Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system
title_full Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system
title_fullStr Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system
title_full_unstemmed Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system
title_short Re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the German healthcare system
title_sort re-focusing the ethical discourse on personalized medicine: a qualitative interview study with stakeholders in the german healthcare system
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681604/
https://www.ncbi.nlm.nih.gov/pubmed/23705623
http://dx.doi.org/10.1186/1472-6939-14-20
work_keys_str_mv AT schleidgensebastian refocusingtheethicaldiscourseonpersonalizedmedicineaqualitativeinterviewstudywithstakeholdersinthegermanhealthcaresystem
AT marckmanngeorg refocusingtheethicaldiscourseonpersonalizedmedicineaqualitativeinterviewstudywithstakeholdersinthegermanhealthcaresystem